Actively Recruiting
Evaluating Safety and Preliminary Efficacy of DXC008 in Prostate Cancer and Other Solid Tumors Including Ewing Sarcoma A Phase I, Open-Label, Dose Escalation and Expansion Study
Led by Hangzhou DAC Biotechnology Co., Ltd. · Updated on 2026-09-23
110
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating DXC008 in a phase I, open-label clinical trial involving patients with prostate cancer and other solid tumors, including Ewing sarcoma. The study aims to assess the safety, tolerability, maximum tolerated dose, dose limiting toxicities, recommended phase 2 dose, pharmacokinetics, preliminary anti-tumor activity, and immunogenicity of DXC008. This first-in-human trial targets patients who have failed standard treatments, focusing on those with advanced or metastatic disease. Participants will receive DXC008 administered either once every 2 weeks Q2W in 14-day cycles or once every 3 weeks Q3W in 21-day cycles, depending on cohort assignment. The trial does not use a placebo and involves dose escalation and expansion to evaluate various dosing levels. Treatment continues with close monitoring for adverse events and response until disease progression or unacceptable toxicity. During the study, participants undergo regular assessments including evaluation of dose limiting toxicities within 28 days, monitoring of adverse events for about one year post-infusion, and pharmacokinetic measurements such as serum drug concentration and distribution. Researchers will also measure tumor response using RECIST 1.1 and prostate cancer-specific criteria up to one year. Safety and tolerability are closely tracked, and participants usual medical care continues throughout the study duration, which extends up to April 2030.
CONDITIONS
Brief Title
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Research Team
P
Pengyu Shi, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here